- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04153955
Earlier Mobilization Post Acute Thrombectomy (EMPATHY-II)
October 26, 2023 updated by: Brian Silver
This is a phase III trial trying to determine whether 12-hour bed rest following thrombectomy for ischemic stroke is non-inferior to 24-hour bed rest by measure of outcomes on the modified Rankin Scale (mRS) at 90 days post bed rest.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 years or older
- Received thrombectomy (may have also received intravenous tPA) for a diagnosis of acute ischemic stroke
- TICI 2b/2c/3 score following thromectomy
- Patient and/or Legally Authorized Representative provide consent
Exclusion Criteria:
- TICI 0/1/2a score following thrombectomy
- Venous thromboembolism present at symptom onset
- Pneumonia present at symptom onset
- STEMI at symptom onset
- Positive troponins at symptom onset according to local values
- Bone fracture at symptom onset
- Intubation anticipated or occurred
- Symptomatic intracranial hemorrhage (defined as increase in NIHSS by 4 points or more accompanied by PH2 hemorrhage on imaging) at the time of screening.
- Pre-screening systolic blood pressure < 110 mmHg
- Resting pulse oximetry < 92% (with or without supplemental oxygen)
- Neurological worsening (defined as NIHSS increase of 4 points compared to initial score) prior to screening.
- Baseline modified Rankin Scale score > 2
- Known Pregnancy
- Patient not anticipated to survive 3 months
- Patient not anticipated to follow-up at 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 12-Hour Bed Rest
Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
|
Any movement out of bed
|
|
Active Comparator: 24-Hour Bed Rest
Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
|
Any movement out of bed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
90 Day Modified Rankin Scale (mRS) score
Time Frame: 90 days post bed rest
|
Proportion of patients with a modified Rankin Scale score (min 0, max 5 with 0 being the best outcome) of 0-2 at 90 days
|
90 days post bed rest
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pneumonia
Time Frame: Duration of hospitalization stay, average 5 days
|
Determine whether rates of pneumonia are at least similar in the two arms.
Rates will be measured as percentages of the entire population at risk.
|
Duration of hospitalization stay, average 5 days
|
|
Venous Thromboembolism
Time Frame: Duration of hospitalization stay, average 5 days
|
Determine whether rates of Venous Thromboembolism (VTE) are at least similar in the two arms.
Rates will be measured as percentages of the entire population at risk.
|
Duration of hospitalization stay, average 5 days
|
|
Neurological Worsening
Time Frame: Duration of hospitalization stay, average 5 days
|
Determine whether rates of neurological worsening are at least similar in the two arms.
Rates will be measured as percentages of the entire population at risk.
|
Duration of hospitalization stay, average 5 days
|
|
Readmission
Time Frame: 90 days post bed rest
|
Determine whether rates of readmission are at least similar in the two arms.
|
90 days post bed rest
|
|
Length of Stay
Time Frame: Duration of hospitalization stay, average 5 days
|
Determine whether length of hospital stay are at least similar in the two arms.
This will be measured in days.
|
Duration of hospitalization stay, average 5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Brian Silver, MD, UMass Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
October 21, 2019
First Submitted That Met QC Criteria
November 4, 2019
First Posted (Actual)
November 6, 2019
Study Record Updates
Last Update Posted (Actual)
October 30, 2023
Last Update Submitted That Met QC Criteria
October 26, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H00018239
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University Hospital HeidelbergCompletedAcute Ischemic Stroke | Acute Ischemic Stroke AIS | Acute Ischemic Stroke PatientsGermany
Clinical Trials on Mobilization
-
Isra UniversityUnknown
-
Riphah International UniversityRecruitingAdhesive CapsulitisPakistan
-
Youngstown State UniversityRecruitingLow Back Pain | Musculoskeletal ManipulationsUnited States
-
Riphah International UniversityCompletedAdhesive Capsulitis of ShoulderPakistan
-
Karabuk UniversityCompletedNeck Pain | Disability Physical | KinesiophobiaTurkey
-
Universidade Federal do CearaCompletedTemporomandibular DisordersBrazil
-
Universidad Rey Juan CarlosCompletedOsteoarthritis, Knee | Musculoskeletal ManipulationsSpain
-
Dow University of Health SciencesRecruitingCarpal Tunnel SyndromePakistan
-
Istinye UniversityCompleted
-
University of AlcalaCompleted